RR001

PreclinicalSmall molecule

RR001 is one of 2 small molecule programs targeting Locally Advanced Pancreatic Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Pancreatic AdenocarcinomaRecruiting

Locally Advanced Pancreatic AdenocarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Locally Advanced Pancreatic Adenocarcinoma

#DrugCompanyPhaseTrials

Peposertib

Merck & Co.

Preclinical

1 2

RR001

EEIR Biotherapies s.r.l.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Locally Advanced Pancreatic Adenocarcinoma

NCT06861452

Clinical

Trials by Indication[1]

Locally Advanced Pancreatic Adenocarcinoma1 trial

RR001 in Combination With Chemotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study

Recruiting·EEIR Biotherapies s.r.l.·Preclinical·NCT06861452·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RR001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RR001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RR001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EIR Biotherapies s.r.l. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEIR Biotherapies s.r.l.

RR001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Locally Advanced Pancreatic Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News